サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1193044

肝疾患診断市場：技術別（画像診断、ラボ検査、内視鏡検査、生検）、エンドユーザー別（病院、研究所、その他）：世界の機会分析および産業予測、2021-2031年

Liver Disease Diagnostics Market By Technique (imaging, laboratory tests, endoscopy, biopsy), By End Use (hospitals, laboratories, others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 203 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
肝疾患診断市場：技術別（画像診断、ラボ検査、内視鏡検査、生検）、エンドユーザー別（病院、研究所、その他）：世界の機会分析および産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 203 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肝疾患診断薬市場は、2021年に345億2,040万米ドルとなり、2031年には619億6,210万米ドルに達し、2022年から2031年にかけてCAGR 6.1%で成長すると予測されます。

肝臓は身体の重要な臓器であり、ビリルビン、コレステロール、ホルモン、薬物として排泄する胆汁の生成＆排泄など500以上の機能と主要な機能を有しています。感染と戦い、毒素を排除し、血液の浄化を助ける。肝臓疾患は、肝臓に影響を及ぼす様々な複雑な症状で構成されています。肝機能障害は致命的であり、A型肝炎、B型肝炎、C型肝炎、非アルコール性脂肪性肝疾患、肝臓がん、胆管がん、肝細胞腺腫、肝硬変など様々な急性および慢性疾患を引き起こす可能性があります。肝疾患の原因は、感染症（寄生虫、ウイルス）、慢性アルコール中毒、肝臓への脂肪蓄積、免疫系の異常、遺伝（ヘモクロマトーシス、高オキシ尿、ウィルソン病）などがあります。

肝疾患診断には、画像診断、臨床検査、内視鏡検査、生検など様々な手法が用いられます。肝疾患の診断にMRI、CTスキャン、検査室などの画像診断の利用が増加し、肝疾患診断薬市場の成長を後押ししています。

肝臓疾患診断市場の成長を促進する主な要因としては、技術的進歩の上昇、肝炎、B型慢性肝炎、C型慢性肝炎、非アルコール性脂肪性肝疾患（NAFLD）などの慢性肝疾患の有病率の上昇などが挙げられます。また、その他の肝疾患として、浸潤性肝疾患（肝性サルコイドーシス、アミロイドーシスなど）、α-1アンチトリプシン欠損症、原発性胆汁性胆管炎、原発性硬化性胆管炎などがあげられます。

例えば、2022年6月に発表された世界保健機関（WHO）の報告書によると、世界では推定5800万人がC型慢性肝炎ウイルスに感染しており、年間約150万人が新たに感染しているとのことです。また、青年・小児では推定320万人がC型慢性肝炎に感染しているとされています。このような要因が、肝疾患診断薬の需要を高めています。

しかし、不利な診療報酬、訓練を受けた医師や内視鏡医の不足、生検の副作用、肝疾患診断薬に関連する高コストなどの合併症が市場成長の妨げになると予想されます。一方、発展途上国におけるアンメットメディカルな需要や新興国における有利なビジネスチャンスは、今後世界中の肝疾患診断薬メーカーに大きなビジネスチャンスをもたらすと予想されます。

さらに、慢性肝疾患、肝炎、肝がんの有病率の上昇、創薬開発における研究開発投資の増加、肝疾患の低侵襲診断法に関する認知度の上昇により、ヘルスケア事業の成長が予測されます。このため、予測期間中に主要企業がこの市場に投資することで、有益な機会を提供できると予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 肝疾患診断薬市場：技術別

  • 概要
    • 市場規模・予測
  • イメージング
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • ラボラトリーテスト
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 内視鏡検査
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 生検
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第5章 肝疾患診断薬市場： エンドユーザー別

  • 概要
    • 市場規模および予測
  • 病院
    • 主な市場動向・成長要因・機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • ラボラトリー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第6章 肝疾患診断薬市場：地域別

  • 概要
    • 市場規模および予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測：技術別
    • 北米市場規模・予測：エンドユーザー別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主要動向と機会
    • 欧州の市場規模・予測：技術別
    • 欧州市場規模・予測：エンドユーザー別
    • 欧州市場規模・予測：国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他欧州
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模と予測：技法別
    • アジア太平洋地域の市場規模・予測：エンドユーザー別
    • アジア太平洋地域の市場規模・予測：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • オーストラリア
      • その他のアジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：技法別
    • LAMEAの市場規模・予測：エンドユーザー別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • その他のLAMEA地域

第7章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主な発展

第8章 企業プロファイル

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Cosara Diagnostics Pvt Ltd
  • Echosens
  • Meril Life Sciences Pvt. Ltd.
  • PerkinElmer
  • Qiagen N.V.
  • Siemen's AG
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare
図表

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 2. LIVER DISEASE DIAGNOSTICS MARKET, FOR IMAGING, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. LIVER DISEASE DIAGNOSTICS MARKET FOR IMAGING, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORY TESTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET, FOR ENDOSCOPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. LIVER DISEASE DIAGNOSTICS MARKET FOR ENDOSCOPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. LIVER DISEASE DIAGNOSTICS MARKET, FOR BIOPSY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. LIVER DISEASE DIAGNOSTICS MARKET FOR BIOPSY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 11. LIVER DISEASE DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. LIVER DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. LIVER DISEASE DIAGNOSTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. LIVER DISEASE DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. LIVER DISEASE DIAGNOSTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 22. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 23. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 24. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 32. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 33. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 34. UK LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 35. UK LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 36. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 37. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 38. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 39. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 40. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 41. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 42. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 43. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 44. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 45. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 46. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 47. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 48. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 49. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 50. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 51. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 52. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 53. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 54. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 55. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 56. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 57. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 58. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 59. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 60. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 61. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 62. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 63. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 64. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 66. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 67. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 68.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 69.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 70.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 71.ABBOTT LABORATORIES: NET SALES,
  • TABLE 72.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 73.BIO-RAD LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 74.BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 75.BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 76.BIO-RAD LABORATORIES INC.: NET SALES,
  • TABLE 77.BIO-RAD LABORATORIES INC.: KEY STRATERGIES
  • TABLE 78.COSARA DIAGNOSTICS PVT LTD: COMPANY SNAPSHOT
  • TABLE 79.COSARA DIAGNOSTICS PVT LTD: OPERATING SEGMENTS
  • TABLE 80.COSARA DIAGNOSTICS PVT LTD: PRODUCT PORTFOLIO
  • TABLE 81.COSARA DIAGNOSTICS PVT LTD: NET SALES,
  • TABLE 82.COSARA DIAGNOSTICS PVT LTD: KEY STRATERGIES
  • TABLE 83.ECHOSENS: COMPANY SNAPSHOT
  • TABLE 84.ECHOSENS: OPERATING SEGMENTS
  • TABLE 85.ECHOSENS: PRODUCT PORTFOLIO
  • TABLE 86.ECHOSENS: NET SALES,
  • TABLE 87.ECHOSENS: KEY STRATERGIES
  • TABLE 88.MERIL LIFE SCIENCES PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 89.MERIL LIFE SCIENCES PVT. LTD.: OPERATING SEGMENTS
  • TABLE 90.MERIL LIFE SCIENCES PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 91.MERIL LIFE SCIENCES PVT. LTD.: NET SALES,
  • TABLE 92.MERIL LIFE SCIENCES PVT. LTD.: KEY STRATERGIES
  • TABLE 93.PERKINELMER: COMPANY SNAPSHOT
  • TABLE 94.PERKINELMER: OPERATING SEGMENTS
  • TABLE 95.PERKINELMER: PRODUCT PORTFOLIO
  • TABLE 96.PERKINELMER: NET SALES,
  • TABLE 97.PERKINELMER: KEY STRATERGIES
  • TABLE 98.QIAGEN N.V.: COMPANY SNAPSHOT
  • TABLE 99.QIAGEN N.V.: OPERATING SEGMENTS
  • TABLE 100.QIAGEN N.V.: PRODUCT PORTFOLIO
  • TABLE 101.QIAGEN N.V.: NET SALES,
  • TABLE 102.QIAGEN N.V.: KEY STRATERGIES
  • TABLE 103.SIEMEN'S AG: COMPANY SNAPSHOT
  • TABLE 104.SIEMEN'S AG: OPERATING SEGMENTS
  • TABLE 105.SIEMEN'S AG: PRODUCT PORTFOLIO
  • TABLE 106.SIEMEN'S AG: NET SALES,
  • TABLE 107.SIEMEN'S AG: KEY STRATERGIES
  • TABLE 108.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 109.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 110.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 111.THERMO FISHER SCIENTIFIC INC.: NET SALES,
  • TABLE 112.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
  • TABLE 113.TRIVITRON HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 114.TRIVITRON HEALTHCARE: OPERATING SEGMENTS
  • TABLE 115.TRIVITRON HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 116.TRIVITRON HEALTHCARE: NET SALES,
  • TABLE 117.TRIVITRON HEALTHCARE: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031
  • FIGURE 3.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.LIVER DISEASE DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.LIVER DISEASE DIAGNOSTICS MARKET,BY TECHNIQUE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF IMAGING LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF LABORATORY TESTS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BIOPSY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 17.LIVER DISEASE DIAGNOSTICS MARKET,BY END USE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF LABORATORIES LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 21.LIVER DISEASE DIAGNOSTICS MARKET BY REGION,2021
  • FIGURE 22.U.S. LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 23.CANADA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 24.MEXICO LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 25.GERMANY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 26.FRANCE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 27.UK LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 28.ITALY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 29.SPAIN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 30.REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 31.CHINA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 32.JAPAN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 33.INDIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 34.SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 35.AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 36.REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 37.BRAZIL LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 38.SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 39.SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45.COMPETITIVE DASHBOARD
  • FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 47.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 48.BIO-RAD LABORATORIES INC..: NET SALES ,($MILLION)
  • FIGURE 49.COSARA DIAGNOSTICS PVT LTD.: NET SALES ,($MILLION)
  • FIGURE 50.ECHOSENS.: NET SALES ,($MILLION)
  • FIGURE 51.MERIL LIFE SCIENCES PVT. LTD..: NET SALES ,($MILLION)
  • FIGURE 52.PERKINELMER.: NET SALES ,($MILLION)
  • FIGURE 53.QIAGEN N.V..: NET SALES ,($MILLION)
  • FIGURE 54.SIEMEN'S AG.: NET SALES ,($MILLION)
  • FIGURE 55.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
  • FIGURE 56.TRIVITRON HEALTHCARE.: NET SALES ,($MILLION)
目次
Product Code: A08425

The liver disease diagnostics market was valued at $34,520.4 million in 2021 and is estimated to reach $61,962.1 million by 2031, growing at a CAGR of 6.1% from 2022 to 2031. 

The liver is a vital organ of the body and has more than 500 functions and primary functions such as bile production & excretion, as excretion as bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins, and helps in blood purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to infection (parasites and viruses), chronic alcohol abuse, fat accumulation in the liver, immune system abnormality, and inheritance (hemochromatosis, hyperoxaluria, and Wilson's disease)

Various techniques are used for the diagnosis of liver diseases such as imaging, laboratory tests, endoscopy, and biopsy. An increase in the use of imaging such as MRI, CT scan, and laboratory for the diagnosis of liver diseases boosts the growth of the liver disease diagnostics market.

Major factors that drive the growth of the liver disease diagnostics market include a rise in technological advancements, and an increase in the prevalence rate of chronic liver diseases such as hepatitis, chronic hepatitis B, chronic hepatitis C, and nonalcohol-related fatty liver disease (NAFLD). In addition, other liver diseases include infiltrative liver disorders (e.g., hepatic sarcoidosis and amyloidosis), alpha-1 antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis.

For instance, according to a report by the World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people had chronic hepatitis C virus infection, with around 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have chronic hepatitis C infection. Hence, such factors increase the demand for liver disease diagnostics.

However, unfavorable reimbursements, as well as complications such as the dearth of trained physicians & endoscopists, side effects of biopsy, and high costs associated with liver disease diagnostic products, are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for liver disease diagnostics manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in the prevalence of chronic liver diseases, hepatitis, and liver cancer; an increase in R&D investments in drug discovery & development, and a rise in awareness regarding the minimally invasive diagnostic procedure for liver diseases. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The liver disease diagnostics market is segmented on the basis of technique, end user, and region. On the basis of technique, the market is classified into imaging, laboratory tests, endoscopy, and biopsy. Depending on the end user, it is fragmented into hospitals, laboratories, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd, Echosens, Fujifilm Holdings Corporation, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens AG, Thermo Fisher Scientific Inc., and Trivitron Healthcare.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the liver disease diagnostics market analysis from 2021 to 2031 to identify the prevailing liver disease diagnostics market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the liver disease diagnostics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global liver disease diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technique

  • endoscopy
  • biopsy
  • imaging
  • laboratory tests

By End Use

  • hospitals
  • laboratories
  • others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbott Laboratories
    • Bio-Rad Laboratories Inc.
    • Cosara Diagnostics Pvt Ltd
    • Echosens
    • Meril Life Sciences Pvt. Ltd.
    • PerkinElmer
    • Qiagen N.V.
    • Siemen's AG
    • Thermo Fisher Scientific Inc.
    • Trivitron Healthcare

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 imaging
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 laboratory tests
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 endoscopy
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 biopsy
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: LIVER DISEASE DIAGNOSTICS MARKET, BY END USE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 hospitals
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 laboratories
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: LIVER DISEASE DIAGNOSTICS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Technique
    • 6.2.3 North America Market size and forecast, by End Use
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Technique
      • 6.2.4.1.2 Market size and forecast, by End Use
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Technique
      • 6.2.4.2.2 Market size and forecast, by End Use
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Technique
      • 6.2.4.3.2 Market size and forecast, by End Use
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Technique
    • 6.3.3 Europe Market size and forecast, by End Use
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Technique
      • 6.3.4.1.2 Market size and forecast, by End Use
      • 6.3.4.2 France
      • 6.3.4.2.1 Market size and forecast, by Technique
      • 6.3.4.2.2 Market size and forecast, by End Use
      • 6.3.4.3 UK
      • 6.3.4.3.1 Market size and forecast, by Technique
      • 6.3.4.3.2 Market size and forecast, by End Use
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Market size and forecast, by Technique
      • 6.3.4.4.2 Market size and forecast, by End Use
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Market size and forecast, by Technique
      • 6.3.4.5.2 Market size and forecast, by End Use
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Technique
      • 6.3.4.6.2 Market size and forecast, by End Use
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Technique
    • 6.4.3 Asia-Pacific Market size and forecast, by End Use
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Market size and forecast, by Technique
      • 6.4.4.1.2 Market size and forecast, by End Use
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Market size and forecast, by Technique
      • 6.4.4.2.2 Market size and forecast, by End Use
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Technique
      • 6.4.4.3.2 Market size and forecast, by End Use
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Market size and forecast, by Technique
      • 6.4.4.4.2 Market size and forecast, by End Use
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Market size and forecast, by Technique
      • 6.4.4.5.2 Market size and forecast, by End Use
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Market size and forecast, by Technique
      • 6.4.4.6.2 Market size and forecast, by End Use
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Technique
    • 6.5.3 LAMEA Market size and forecast, by End Use
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Technique
      • 6.5.4.1.2 Market size and forecast, by End Use
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Technique
      • 6.5.4.2.2 Market size and forecast, by End Use
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Market size and forecast, by Technique
      • 6.5.4.3.2 Market size and forecast, by End Use
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Market size and forecast, by Technique
      • 6.5.4.4.2 Market size and forecast, by End Use

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Abbott Laboratories
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Bio-Rad Laboratories Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Cosara Diagnostics Pvt Ltd
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 Echosens
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Meril Life Sciences Pvt. Ltd.
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 PerkinElmer
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Qiagen N.V.
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Siemen's AG
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 Thermo Fisher Scientific Inc.
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Trivitron Healthcare
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments